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background: Elevated levels of fibroblast growth factor-23 (FGF23) are associated with all-cause mortality and incident heart failure in individuals 
with or without chronic kidney disease. We aimed to investigate the association of serum FGF23 concentrations with disease severity and long-term 
outcome in patients with stable heart failure.
Methods: Serum levels of C-term FGF23 (Ct-FGF23) concentrations, inorganic phosphate (Pi), parathormone (PTH), and 25-hydroxy-vitamin-D 
(25(OH)D) (age 48±15 years; 70% male; NYHA class I 27,8%, NYHA class II 43,4%, NYHA class III/IV 28,8%; LV-EF 34±15%; eGFR 85±23,7 ml/
min/1,73m2) of 208 patients with stable, non-ischemic heart failure were measured
results: Median Ct-FGF23 levels were 18,2 RU/ml (7.5-40,8RU/ml). A significant dose-response relationship was found between median Ct-FGF23 
levels and increasing NYHA class (I: 11.9 RU/ml, II: 15,8 RU/ml, III/IV: 38,8 RU/ml; p<0,001). Ct-FGF-23 significantly correlated with NTproBNP 
(r=0,307, p<0,001), central venous pressure (CVP), mean pulmonary arterial pressure (mPAP), pulmonary capillary wedge pressure (PCWP) and 
inversely correlated with cardiac output (CO) after adjustment for renal function (eGFR) and Pi. Correlations with CO (p=0,010) and CVP (p=0,024) 
remained robust in multivariate regression analysis. Ct-FGF23 was associated with PTH (r=0.238, p=0.001), 25(OH)D (r=-0.154, p=0.041) and eGFR 
(r=-0.345, p=<0.001) with PTH and eGFR as independent variables. LnCt-FGF23 was significantly related with the combined endpoint of death or 
heart transplantation (Hazard ratio 1.452 [1.029 to 2.048]; p=0.034). This relationship was independent of Pi, PTH, 25(OH)D, age and sex.
conclusions: The phosphatonin Ct-FGF23 is strongly associated with disease severity and long-term outcome in patients with stable heart failure. 
Further studies are needed to evaluate the pathophysiologic role of Ct-FGF23 and its potential as a biomarker in heart failure.
